Sanofi-Aventis expands Regeneron research deal to $1 billion

11 Nov 2009

1

French drug maker Sanofi-Aventis is expanding and extending its existing global collaboration with Regeneron Pharmaceuticals and pay it an additional $1 billion over eight years for discovering new drugs.

Paris-based Sanofi-Aventis and Regeneron Pharmaceuticals said yesterday that that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialise fully-human therapeutic monoclonal antibodies.

Sanofi will increase its annual funding commitment from $100 million to $160 million beginning in 2010, and the research funding will now extend through 2017.

Both the pharmaceutical companies aim to advance an average of four to five antibodies into clinical development each year. In addition to its VelocImmune technology, Regeneron will contribute to the collaboration its next generation technologies related to antibody generation.

Sanofi holds nearly 20 per cent stake in New York City-based Regeneron, but cannot increase its stake to more than 30 per cent under a standstill agreement.

Sanofi said that it has an option to extend the discovery program for up to an additional three years for further antibody development and preclinical activities.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more